Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies

Expert Review of Vaccines

Volumn 6, Issue 2, 2007, Pages 153-168

  Bade, Steffen ^a   Frey, Andreas ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Creutzfeldt Jakob disease; IgG; Immunization; Prion; Prophylaxis; Scrapie; sIgA; Therapy; Transmissible spongiform encephalopathies; Vaccination

Indexed keywords

CELL WALL SKELETON; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; FREUND ADJUVANT; HEAT LABILE ENTEROTOXIN; HEAT SHOCK PROTEIN 70; HELIX 1 PEPTIDE; IMS 1313; KEYHOLE LIMPET HEMOCYANIN; LIPOFECTIN; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 BINDING PRION PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6H4; MONOCLONAL ANTIBODY 7D9; MONOCLONAL ANTIBODY ICSM35; MONOCLONAL ANTIBODY PRION PROTEIN; MONTANIDE; PHOSPHORYL LIPID A; PRION PROTEIN; RECOMBINANT PRION PROTEIN 132-242; RECOMBINANT PRION PROTEIN 23-230; RECOMBINANT PRION PROTEIN 23-231; RECOMBINANT PRION PROTEIN 25-242; RECOMBINANT PRION PROTEIN 90-231; RECOMBINANT VACCINE; SALMONELLOSIS VACCINE; TREHALOSE DICHORYNOMYCOLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN SPONGIOSIS; CHRONIC WASTING DISEASE; COST BENEFIT ANALYSIS; CREUTZFELDT JAKOB DISEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MEGADOSE; ECONOMIC EVALUATION; EPIDEMIC; ERADICATION THERAPY; FELINE SPONGIFORM ENCEPHALOPATHY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PREVALENCE; PRION; PRION DISEASE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SCRAPIE; SINGLE DRUG DOSE; TRANSMISSIBLE MINK ENCEPHALOPATHY; VARIANT CREUTZFELDT JAKOB DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DESIGN; HUMANS; IMMUNIZATION, PASSIVE; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS; VACCINATION; ZOONOSES;

EID: 34247234606     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.2.153     Document Type: Review

References (99)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 216(4542), 136-144 (1982).
2. Papassotiropoulos A, Wollmer MA, Aguzzi A et al. The prion gene is associated with human long-term memory. Hum. Mol. Genet. 14(15), 2241-2246 (2005).
3. Martins VR, Linden R, Prado MA et al. Cellular prion protein: on the road for functions. FEBS Lett. 512(1-3), 25-28 (2002).
4. Bueler H, Aguzzi A, Sailer A et al. Mice devoid of PrP are resistant to scrapie. Cell 73(7), 1339-1347 (1993).
5. Prusiner SB, Groth D, Serban A et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl Acad. Sci. USA 90(22), 10608-10612 (1993).
6. Glatzel M, Heppner FL, Albers KM, Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 31(1), 25-34 (2001).
7. Mabbott NA, Macpherson GG. Prions and their lethal journey to the brain. Nat. Rev. Microbiol. 4(3), 201-211 (2006). •Comprehensive overview of the pathogenesis of transmissible spongiform encephalopathies (TSE).
8. Pan KM, Baldwin M, Nguyen J et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl Acad. Sci. USA 90(23), 10962-10966 (1993).
9. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 35(1), 57-62 (1983).
10. Taylor DM, Fraser H, McConnell I et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch. Virol. 139(3-4), 313-326 (1994).
11. Brown P, Gajdusek DC. Survival of scrapie virus after 3 years' interment. Lancet 337(8736), 269-270 (1991).
12. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67(3), 389-393 (2006).
13. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347(9006), 921-925 (1996).
14. Zeidler M, Stewart GE, Barraclough CR et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet 350(9082), 903-907 (1997).
15. Lasmezas CI, Deslys JP, Demaimay R et al. BSE transmission to macaques. Nature 381(6585), 743-744 (1996).
16. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389(6650), 498-501 (1997).
17. Myles S, Douglas MJ, Ward HJ, Campbell H, Will RG. Variant Creutzfeldt-Jakob disease: costs borne by families. Health Soc. Care Community 10(2), 91-98 (2002).
18. Collinge J, Whitfield J, McKintosh E et al. Kuru in the 21st century - an acquired human prion disease with very long incubation periods. Lancet 367(9528), 2068-2074 (2006).
19. Brown P, Abee CR. Working with transmissible spongiform encephalopathy agents. ILAR J. 46(1), 44-52 (2005).
20. Thomzig A, Cardone F, Kruger D et al. Pathological prion protein in muscles of hamsters and mice infected with rodent-adapted BSE or vCJD. J. Gen. Virol. 87(Pt 1), 251-254 (2006).
21. Angers RC, Browning SR, Seward TS et al. Prions in skeletal muscles of deer with chronic wasting disease. Science 311(5764), 1117 (2006).
22. Heikenwalder M, Zeller N, Seeger H et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 307(5712), 1107-1110 (2005).
23. Mathiason CK, Powers JG, Dahmes SJ et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314(5796), 133-136 (2006).
24. Miller MW, Williams ES, Hobbs NT, Wolfe LL. Environmental sources of prion transmission in mule deer. Emerg. Infect. Dis. 10(6), 1003-1006 (2004).
25. Bartz JC, Marsh RF, McKenzie DI, Aiken JM. The host range of chronic wasting disease is altered on passage in ferrets. Virology 251(2), 297-301 (1998).
26. Belay ED, Maddox RA, Williams ES et al. Chronic wasting disease and potential transmission to humans. Emerg. Infect. Dis.10(6), 977-984 (2004).
27. Diringer H, Roehmel J, Beekes M. Effect of repeated oral infection of hamsters with scrapie. J. Gen. Virol. 79(Pt 3), 609-612 (1998).
28. Jacquemot C, Cuche C, Dormont D, Lazarini F. High incidence of scrapie induced by repeated injections of subinfectious prion doses. J. Virol. 79(14), 8904-8908 (2005).
29. Heppner FL, Christ AD, Klein MA et al. Transepithelial prion transport by M cells. Nat. Med. 7(9), 976-977 (2001).
30. Bergstrom AL, Jensen TK, Heegaard PM et al. Short-term study of the uptake of PrP(Sc) by the Peyer's patches in hamsters after oral exposure to scrapie. J. Comp. Pathol. 134(2-3), 126-133 (2006).
31. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86(3), 345-348 (1996).
32. Beekes M, McBride PA. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci. Lett. 278(3), 181-184 (2000).
33. Huang FP, Farquhar CF, Mabbott NA, Bruce ME, MacPherson GG. Migrating intestinal dendritic cells transport PrP(Sc) from the gut. J. Gen. Virol. 83(Pt 1), 267-271 (2002).
34. Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2(4), 361-367 (2001).
35. Scherbel C, Pichner R, Groschup MH et al. Degradation of scrapie associated prion protein (PrP(Sc)) by the gastrointestinal microbiota of cattle. Vet. Res. 37(5), 695-703 (2006).
36. Mishra RS, Basu S, Gu Y et al. Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J. Neurosci. 24(50), 11280-11290 (2004).
37. Prinz M, Heikenwalder M, Junt T et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425(6961), 957-962 (2003).
38. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
39. Phalipon A, Cardona A, Kraehenbuhl JP et al. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 17(1), 107-115 (2002).
40. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(Suppl. 4), S45-S53 (2005).
41. Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294(5540), 178-182 (2001).
42. Mallucci G, Dickinson A, Linehan J et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646), 871-874 (2003).
43. Souan L, Tal Y, Felling Y et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31(8), 2338-2346 (2001).
44. Koller MF, Grau T, Christen P. Induction of antibodies against murine full-length prion protein in wild-type mice. J. Neuroimmunol. 132(1-2), 113-116 (2002).
45. Sigurdsson EM, Brown DR, Daniels M et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161(1), 13-17 (2002). •Demonstrates that an active systemic immunization is able to prolong the asymptomatic incubation phase after systemic infection with prions.
46. Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14670-14676 (2004).
47. Gilch S, Wopfner F, Renner-Muller I et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278(20), 18524-18531 (2003).
48. Nikles D, Bach P, Boller K et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J. Virol. 79(7), 4033-4042 (2005).
49. Andrievskaia O, McRae H, Elmgren C et al. Generation of antibodies against bovine recombinant prion protein in various strains of mice. Clin. Vaccine Immunol. 13(1), 98-105 (2006).
50. Ishibashi D, Yamanaka H, Yamaguchi N et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine 25(6), 985-992 (2006).
51. Rosset MB, Ballerini C, Gregoire S et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol. 172(9), 5168-5174 (2004).
52. Gregoire S, Bergot AS, Feraudet C et al. The murine B cell repertoire is severely selected against endogenous cellular prion protein. J. Immunol. 175(10), 6443-6449 (2005).
53. Tal Y, Souan L, Cohen IR et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. 71(2), 286-290 (2003).
54. Oboznaya MB, Gilch S, Titova MA et al. Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP(Sc) propagation in prion-infected cells. Cell. Mol. Neurobiol. DOI: 10.1007/s10571-006- 9108-y (2007) (Epub ahead of print).
55. Arbel M, Lavie V, Solomon B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J. Neuroimmunol. 144(1-2), 38-45 (2003).
56. Bainbridge J, Jones N, Walker B. Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin. Exp. Immunol. 137(2), 298-304 (2004).
57. Schwarz A, Kratke O, Burwinkel M et al.. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350(3), 187-189 (2003). •Demonstrates that an active systemic immunization can have a prophylactic effect on oral acquisition of TSE.
58. Magri G, Clerici M, Dall'ara P et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 23(22), 2862-2868 (2005).
59. Muller S, Kehm R, Handermann M et al. Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC. Virus Genes 30(2), 279-296 (2005).
60. Fernandez-Borges N, Brun A, Whitton JL et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J. Virol. 80(20), 9970-9976 (2006).
61. Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133(2), 413-421 (2005). •Demonstrates that an active mucosal immunization can protect against TSE.
62. Bade S, Baier M, Boetel T, Frey A. Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine 24(9), 1242-1253 (2006). •Demonstrates that an active mucosal immunization attenuates the disease and that the stability of the prion protein (PrP) antigen is crucial for the induction of anti-PrP antibodies via a mucosal vaccination.
63. Baier M, Norley S, Schultz J et al. Prion diseases: infectious and lethal doses following oral challenge. J. Gen. Virol. 84(Pt 7), 1927-1929 (2003).
64. Yamanaka H, Ishibashi D, Yamaguchi N et al. Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin. Vaccine 24(15), 2815-2823 (2006).
65. Sigurdsson EM, Sy MS, Li R et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336(3), 185-187 (2003).
66. Pankiewicz J, Prelli F, Sy MS et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci. 23(10), 2635-2647 (2006).
67. White AR, Enever P, Tayebi M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422(6927), 80-83 (2003). •Demonstrates that repeated passive immunizations with high doses of anti-PrP antibodies can clear the infection and protect from disease.
68. Kascsak RJ, Rubenstein R, Merz PA et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J. Virol. 61(12), 3688-3693 (1987).
69. Khalili-Shirazi A, Quaratino S, Londei M et al. Protein conformation significantly influences immune responses to prion protein. J. Immunol. 174(6), 3256-3263 (2005).
70. Miyamoto K, Nakamura N, Aosasa M et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem. Biophys. Res. Commun. 335(1), 197-204 (2005).
71. Korth C, Stierli B, Streit P et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 390(6655), 74-77 (1997).
72. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98(16), 9295-9299 (2001).
73. Perrier V, Solassol J, Crozet C et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J. Neurochem. 89(2), 454-463 (2004).
74. Kim CL, Umetani A, Matsui T et al. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320(1), 40-51 (2004).
75. Kim CL, Karino A, Ishiguro N et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 85(Pt 11), 3473-3482 (2004).
76. Feraudet C, Morel N, Simon S et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J. Biol. Chem. 280(12), 11247-11258 (2005).
77. Beringue V, Vilette D, Mallinson G et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J. Biol. Chem. 279(38), 39671-39676 (2004).
78. Knight DM, Wagner C, Jordan R et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. 32(16), 1271-1281 (1995).
79. Peretz D, Williamson RA, Kaneko K et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412(6848), 739-743 (2001).
80. Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303(5663), 1514-1516 (2004).
81. Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol. 79(13), 8330-8338 (2005).
82. Cardinale A, Filesi I, Vetrugno V et al. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J. Biol. Chem. 280(1), 685-694 (2005).
83. Vetrugno V, Cardinale A, Filesi I et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun. 338(4), 1791-1797 (2005).
84. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108(2), 184-190 (2001).
85. Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9(7), 893-899 (2003).
86. Williamson RA, Peretz D, Pinilla C et al. Mapping the prion protein using recombinant antibodies. J. Virol. 72(11), 9413-9418 (1998).
87. Novitskaya V, Makarava N, Bellon A et al. Probing the conformation of the prion protein within a single amyloid fibril using a novel immunoconformational assay. J. Biol. Chem. 281(22), 15536-15545 (2006).
88. Zanusso G, Liu D, Ferrari S et al. Prion protein expression in different species: analysis with a panel of new mAbs. Proc. Natl Acad. Sci. USA 95(15), 8812-8816 (1998).
89. Li R, Liu T, Wong BS et al. Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J. Mol. Biol. 301(3), 567-573 (2000).
90. Pan T, Li R, Kang SC et al. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion. J. Neurochem. 90(5), 1205-1217 (2004).
91. Pan T, Wong P, Chang B et al. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J. Virol. 79(2), 934-943 (2005).
92. Beringue V, Mallinson G, Kaisar M et al. Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 126(Pt 9), 2065-2073 (2003).
93. World organization for animal health (OIE). Number of cases of BSE reported in the UK www.oie.int/eng/info/en_esbru.htm
94. World organization for animal health (OIE). Number of reported cases of BSE worldwide www.oie.int/eng/info/en_esbmonde.htm
95. EUROPA. Food safety. Biological safety of Food - BSE ec.europa.eu/food/ food/biosafety/bse/index_en.htm
96. Canadian Food Inspection Agency. Risk assessment on BSE in cattle in Canada. Part C: risk estimation www.inspection.gc.ca/english/sci/ahra/bseris/ bserisc2e.shtml
97. Creutzfeldt Jakob disease Certificates www.cjd.ed.ac.uk/figures.htm
98. Diagnosis, treatment and care of vCJD patients (Vol. 8) www.bseinquiry.gov.uk/report/volume8/chaptec5.htm
99. World organization for animal health (OIE) www.oie.int